Session Details

Session Details

08:00 AM - 09:45 AM - Ballroom 4

Kah-Whye Peng - PhD - Mayo Clinic

Co-Chair

08:00 AM - 09:45 AM - Ballroom 4

Rachel Bailey - Ph.D. - UT Southwestern Medical Center

Co-Chair

08:00 AM - 08:15 AM - Ballroom 4

Maria Escolar - MD, MS - Forge Biologics

REKLAIM, A Phase Ib Clinical Trial Using a Novel Immune Modulation Strategy for Systemic Administration of FBX-101 (AAVrh10.GALC) After Umbilical Cord Blood Transplantation for the Treatment of Infantile Krabbe Disease

08:15 AM - 08:30 AM - Ballroom 4

Richard Roden - PhD - Johns Hopkins University

Therapeutic Vaccination for the Elimination of HPV16+ High Grade Cervical Dysplasia: A Phase I Clinical Trial of the DNA Vaccine pNGVL4aCRTE6E7L2, Administered via the TriGrid^TM Electroporation Device

08:30 AM - 08:45 AM - Ballroom 4

Dingwei Ye - Ph.D - Fudan University Shanghai Cancer Center

Interim Safety and Efficacy of Anti-CD70 CAR-NKT (CGC729) for Patients with Refractory Metastatic Renal Cell Carcinoma

08:45 AM - 09:00 AM - Ballroom 4

Miri Assayag - PhD - Hadassah Medical Center

Academic BCMA-CART Cells HBI0101, a Promising Approach for the Treatment of LC Amyloidosis

09:00 AM - 09:15 AM - Ballroom 4

Reza Nadafi - PhD. - ORCA Therapeutics

Oncolytic Adenovirus ORCA-010 Induces Systemic Tumor-Specific T cell Responses and Activation of the Tumor Microenvironment in Prostate Cancer: A Phase I/IIa Clinical Trial

09:15 AM - 09:30 AM - Ballroom 4

Jingjing Ren - Doctor - Leman Biotech Co.

Updated Clinical Results of Metabolically Armored CD19 CAR-T Cells for Safe and Effective Treatment of Relapsed or Refractory B-Cell Hematological Malignancies at Extremely Low Doses

09:30 AM - 09:45 AM - Ballroom 4

Krish Dewan - MD - Duke University Medical Center

Allograft Overexpression of Modified PD-L1 Confers Tolerance after Heart Transplantation in a Murine Model